HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD-AND-NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD-AND-NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD-AND-NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation schedule could cut treatment time for head and neck cancer patients
Disease control Not yet recruitingThis study tests a shorter, more intense radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this approach is safe and effective at preventing cancer from coming back. About 60 adult…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether adding radiation to immunotherapy before surgery can better shrink tumors in people with advanced head and neck cancer. About 36 adults with treatable but advanced cancer will be randomly assigned to get either the combination or immunotherapy alone befor…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chen Chunyan • Aim: Disease control
Last updated May 17, 2026 00:58 UTC
-
Virus and chemo combo takes on hard-to-treat head and neck cancer
Disease control Not yet recruitingThis study tests a treatment that combines a modified virus (H101) with a procedure called TACE (chemoembolization) for people with recurrent or metastatic head and neck cancer that hasn't responded to at least two prior treatments. The goal is to kill tumor cells and activate th…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for head and neck cancer patients who Can't take standard chemo
Disease control Not yet recruitingThis study tests two different treatments for people with advanced head and neck cancer who cannot receive the standard drug cisplatin. Participants will get radiation therapy along with either the targeted drug cetuximab or a combination of two chemotherapy drugs, carboplatin an…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo shows promise in shrinking head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a new drug (becotatug vedotin) alone or with immunotherapy before surgery can shrink tumors in people with advanced head and neck cancer. About 120 adults who have not had prior treatment will receive the drugs before their planned surgery. The goa…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called QLS5316 in about 300 people with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New triple therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether giving three treatments together before surgery can improve outcomes for people with advanced head and neck cancer. Participants will receive radiation, an immunotherapy drug (pembrolizumab), and an experimental drug (ficerafusp alfa) before standard surg…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo aims to keep head and neck cancer from coming back
Disease control Not yet recruitingThis study tests whether adding the drug benmelstobart to standard radiation and nimotuzumab after surgery can help prevent head and neck cancer from returning. About 386 adults with intermediate-risk features will take part. The main goal is to see if the combination improves ho…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug cocktail aims to improve survival in advanced head and neck cancer
Disease control Not yet recruitingThis study tests whether combining the immunotherapy drug camrelizumab with either an EGFR antibody or chemotherapy can help people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck squamous cell carcinoma will receive the treatme…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Experimental combo aims to boost immune attack on Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis early-phase study tests a combination of two drugs—decitabine (a chemotherapy that can 'reawaken' genes) and nivolumab (an immunotherapy that helps the immune system fight cancer)—in people with head and neck cancer that has returned or spread and cannot be cured with local …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Kyunghee Burkitt, DO, PhD • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New Triple-Threat attack on head and neck cancer before surgery
Disease control Not yet recruitingThis study is testing a new combination of three drugs given to patients before surgery for locally advanced head and neck cancer. The goal is to see if this pre-surgery treatment can shrink or eliminate the tumor, making surgery more effective and potentially improving long-term…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Apr 06, 2026 14:19 UTC
-
Blood test could spot hidden HPV cancers before symptoms start
Diagnosis Not yet recruitingThis study aims to see if a simple blood test can find HPV-related throat and anal cancers early in men aged 50 and older. Participants will provide blood samples to check for signs of the virus and tumor DNA. If successful, this could lead to a national screening program to catc…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Diagnosis
Last updated May 17, 2026 00:53 UTC
-
New imaging agent targets hard-to-treat cancers in early trial
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody (NTH-2403) that attaches to a protein found on certain cancer cells and their supporting cells. The goal is to see if it can safely light up tumors on scans in people with advanced colorectal, head and neck, lung, or triple-negati…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated May 11, 2026 20:47 UTC
-
Glow-in-the-dark dye could help surgeons spot cancer during operations
Diagnosis Not yet recruitingThis early-phase trial tests a fluorescent dye called ABY-029 that makes cancer cells glow during surgery. The goal is to find the right dose so surgeons can better see and remove head and neck tumors. About 24 adults with operable head and neck cancer will receive a tiny amount …
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Diagnosis
Last updated May 06, 2026 16:03 UTC
-
Could less radiation be better for HPV throat cancer? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether lowering radiation doses to certain areas can reduce side effects for people with HPV-related oropharyngeal cancer, which often has good outcomes. About 132 participants will receive either reduced lymph node radiation, reduced tumor radiation, or both, b…
Matched conditions: HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated May 13, 2026 16:01 UTC